Tag: cancer vaccines market share

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Cancer Vaccines Market Size And Revenue Outlook Through 2030

The cancer vaccines market has seen rapid expansion in its size over recent years. It is projected to grow from $9.36 billion in 2025 to $10.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.9%. This historical growth can be attributed to factors such as the increasing global prevalence of cancer, the limited effectiveness of conventional cancer treatments, rising awareness of cancer immunotherapy, growing investment in oncology research, and early regulatory approvals of cancer vaccines.

The cancer vaccines market is projected for significant expansion over the coming years. This market is anticipated to reach $18.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. This projected expansion during the forecast period stems from progress in vaccine platforms and delivery mechanisms, a greater uptake of individualized cancer vaccines, an increase in clinical pipelines for therapeutic vaccines, enhanced government support for cancer research funding, and a rising need for combined cancer treatments. Key trends anticipated over the forecast period encompass the escalating development of therapeutic cancer vaccines, a heightened emphasis on personalized and targeted immunotherapies, more clinical trials for innovative cancer vaccine technologies, the expansion of prophylactic vaccination initiatives to prevent cancer, and increased partnerships between pharmaceutical firms and research institutions.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer Vaccines Market Demand Drivers: What’s Powering Industry Growth?

Increased government financial backing for research and development is projected to boost the growth of the cancer vaccines market going forward. Government funding refers to monetary resources provided by a government for a specific aim. This funding for R&D is on the rise to stimulate innovation and expedite the development of new technologies and treatments that can address pressing health and economic challenges. Cancer vaccines support government funding for research and development by creating opportunities for investment in both preventive and therapeutic innovations, encouraging increased financial assistance for vaccine research programs. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, which signifies a $408 million increase over 2022. Therefore, the rise in government funding for research and development is driving the expansion of the cancer vaccines market.

Cancer Vaccines Market Segment Trends And Revenue Contributors

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

Cancer Vaccines Market Innovation Trends: What Developments Are Reshaping The Industry?

Major companies operating in the cancer vaccines market are intensifying their efforts to introduce quadrivalent vaccines to maximize revenue in the market. A quadrivalent vaccine is a type of vaccine that offers protection against four different strains or types of a specific virus or bacteria. For instance, in January 2023, Serum Institute of India, an India-based biotechnology company, launched CERVAVAC, which stands as the first made-in-India cervical cancer vaccine. The vaccine is engineered to target HPV types 16 and 18, as well as 6 and 11, strains that are responsible for at least 70% of cervical cancers. The vaccine will be administered by injection in two doses among 9–14-year-olds and three doses for those between 15 and 26.

Cancer Vaccines Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

View The Full Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer Vaccines Market Top Region: Where Does Most Revenue Come From?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Cancer Vaccines Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for cancer vaccines has experienced significant expansion in recent years. Projections indicate that it will rise from $9.36 billion in 2025 to $10.66 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.9%. This historical growth is largely explained by several factors: a rising incidence of cancer worldwide, the constrained efficacy of traditional therapeutic approaches, heightened public understanding of immunotherapy as a treatment option, increased funding directed toward oncology investigations, and early-stage regulatory endorsements granted for cancer vaccines.

The cancer vaccines market is projected to experience significant expansion over the coming years, reaching an estimated value of $18.2 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.3%. This anticipated growth during the forecast period is fueled by progress in vaccine platforms and delivery mechanisms, a growing uptake of customized cancer vaccines, an expanding array of clinical trials for therapeutic vaccines, heightened governmental investment in cancer research, and an increased need for combination cancer therapies. Key developments shaping this period include the accelerated creation of therapeutic cancer vaccines, a heightened emphasis on personalized and targeted immunotherapies, an uptick in clinical investigations into novel vaccine technologies, the broadening of preventive vaccination initiatives for cancer, and strengthened partnerships between pharmaceutical firms and research institutions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer Vaccines Market Expansion Drivers: What Is Shaping Future Growth?

An anticipated rise in governmental investment in research and development is expected to fuel the expansion of the cancer vaccines market moving forward. Government funding refers to financial resources allocated by a government to support specific objectives. This funding for research and development is increasing to foster innovation and speed up the creation of new technologies and treatments aimed at addressing pressing health and economic issues. Cancer vaccines contribute to this government investment by generating avenues for backing preventive and therapeutic innovations, thereby encouraging greater financial support for vaccine research initiatives. For example, in September 2023, the National Cancer Institute, a government agency based in the United States, received a budget of $7.3 billion from the United States Congress for the fiscal year 2023, marking an increase of $408 million compared to 2022. Consequently, the growing government funding for research and development is propelling the advancement of the cancer vaccines market.

Cancer Vaccines Market Segmentation: How Is The Market Structured Across Key Categories?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

Cancer Vaccines Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Key players in the cancer vaccines market are placing a stronger emphasis on developing quadrivalent vaccines as a strategy to boost their market revenues. Quadrivalent vaccines are designed to provide protection against four distinct strains or variants of a given virus or bacteria. A notable example occurred in January 2023, when the Serum Institute of India, a biotechnology firm based in India, introduced CERVAVAC, the country’s first domestically produced cervical cancer vaccine. This vaccine targets HPV types 16 and 18, along with types 6 and 11—strains that account for a minimum of 70% of cervical cancer cases. Its administration schedule includes two doses for individuals aged 9 to 14, and three doses for those between 15 and 26 years old.

Cancer Vaccines Market Competitive Landscape And Leading Companies

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Access The Complete Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer Vaccines Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Cancer Vaccines Market During The Forecast Period?

The market size for cancer vaccines has experienced rapid expansion in recent years. This market is projected to expand from $9.36 billion in 2025 to $10.66 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. Historically, this expansion has been driven by factors such as the increasing global prevalence of cancer, the restricted efficacy of traditional cancer therapies, a heightened understanding of cancer immunotherapy, growing investments in oncology research, and prompt regulatory clearances for cancer vaccines.

The cancer vaccines market is projected to experience substantial expansion in the coming years. This market is predicted to reach a valuation of $18.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. Several factors contribute to this anticipated growth, including advancements in vaccine platforms and delivery mechanisms, a rise in the adoption of personalized cancer vaccines, the expansion of clinical pipelines for therapeutic vaccines, increased government funding for cancer research, and a surging demand for combination cancer therapies. Key trends anticipated during this period encompass the escalating development of therapeutic cancer vaccines, an intensified focus on personalized and targeted immunotherapies, a surge in clinical trials for innovative cancer vaccine technologies, the broadening of preventive vaccination initiatives for cancer prevention, and an increase in collaborations between pharmaceutical companies and research institutions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

What Primary Factors Are Fueling The Expansion Of The Cancer Vaccines Market?

Enhanced financial support from governments for research and development activities is anticipated to fuel the expansion of the cancer vaccines market in the future. Government funding is defined as financial resources allocated by a government for specific purposes. This governmental financial backing for R&D is escalating to foster innovation and expedite the creation of novel technologies and therapies capable of confronting crucial health and economic issues. Cancer vaccines contribute to the efficacy of government R&D funding by generating avenues for investment in both preventative and curative innovations, thereby promoting greater financial commitment to vaccine research initiatives. An illustrative example occurred in September 2023, when the National Cancer Institute, a US-based government entity, secured a budget allocation of $7.3 billion for fiscal year 2023 from the United States Congress, marking a $408 million rise compared to the previous year, 2022. Consequently, the growing government investment in research and development is a key factor stimulating the expansion of the cancer vaccines market.

How Does Segment Analysis Break Down The Cancer Vaccines Market Structure?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

What Trends Are Influencing The Cancer Vaccines Market?

Major companies in the cancer vaccines market are increasingly focused on introducing quadrivalent vaccines to maximize market revenue. A quadrivalent vaccine provides protection against four distinct strains or types of a specific virus or bacteria. For instance, in January 2023, Serum Institute of India, an India-based biotechnology company, unveiled CERVAVAC, the country’s first domestically produced cervical cancer vaccine. This vaccine is formulated to act against HPV types 16 and 18, as well as 6 and 11, which are linked to at least 70% of cervical cancers. The vaccine will be administered through injection in two doses for individuals aged 9–14-year-olds, and three doses for those between 15 and 26.

Who Are The Leading Firms Participating In The Cancer Vaccines Market?

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Access The Complete Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Which Region Commands The Largest Share Of The Cancer Vaccines Market?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

Browse Through More Reports Similar to the Global Cancer Vaccines Market 2026, By The Business Research Company

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Cancer Vaccines Market In 2026, And How Will Its Value Evolve By 2030?

The cancer vaccines market size has experienced rapid growth in recent years. It is anticipated to expand from $9.36 billion in 2025 to $10.66 billion in 2026, at a compound annual growth rate (CAGR) of 13.9%. The historical growth of this market can be attributed to increasing global cancer prevalence, the limited effectiveness of conventional cancer treatments, growing awareness of cancer immunotherapy, rising investment in oncology research, and early regulatory approvals of cancer vaccines.

The cancer vaccines market size is projected for substantial expansion over the coming years. Its valuation is expected to reach $18.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. This anticipated growth is primarily driven by enhancements in vaccine platforms and delivery systems, the escalating embrace of personalized cancer vaccines, the broadening of clinical pipelines for therapeutic vaccines, increased government funding for cancer research, and the rising demand for combination cancer therapies. Significant trends for the forecast period include the increasing development of therapeutic cancer vaccines, a heightened focus on personalized and targeted immunotherapies, a surge in clinical trials for innovative cancer vaccine technologies, the expansion of preventive vaccination programs aimed at cancer prevention, and a growing number of collaborations between pharmaceutical companies and research institutes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

Which Primary Drivers Are Impacting The Cancer Vaccines Market Growth?

Elevated government investment in research and development is projected to propel the expansion of the cancer vaccines market in the coming period. Government funding represents financial resources provided by a government for a specific objective. This financial support for research and development is increasing to foster innovation and accelerate the creation of novel technologies and treatments capable of addressing critical health and economic challenges. Cancer vaccines support government funding for research and development by opening up opportunities for investment in preventive and therapeutic innovations, thereby encouraging greater financial backing for vaccine research programs. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, which constitutes a $408 million increase over 2022. Consequently, the rising government funding for research and development is driving the growth of the cancer vaccines market.

How Are Different Segments Classified In The Cancer Vaccines Market Segment Analysis?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

What Trends Are Influencing The Evolution Of The Cancer Vaccines Market?

Leading companies within the cancer vaccines market are increasingly focusing on introducing quadrivalent vaccines to maximize revenue in the market. A quadrivalent vaccine is defined as a vaccine providing protection against four distinct strains or types of a specific virus or bacteria. For instance, in January 2023, Serum Institute of India, an India-based biotechnology company, launched CERVAVAC, which is the first made-in-India cervical cancer vaccine. This vaccine is formulated to target HPV types 16 and 18, as well as 6 and 11, strains that are responsible for at least 70% of cervical cancers. Its administration will be via injection, with two doses recommended for individuals aged 9–14-year-olds and three doses for those between 15 and 26.

Who Are The Companies Driving Activity In The Cancer Vaccines Market?

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Get The Full Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Which Region Leads The Cancer Vaccines Market In Terms Of Market Share?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Browse Through More Reports Similar to the Global Cancer Vaccines Market 2026, By The Business Research Company

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Cancer Vaccines Market Across 2026–2030?

The cancer vaccines market has experienced rapid expansion in recent years. Its value is expected to rise from $9.36 billion in 2025 to $10.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. This historical growth can be linked to factors such as the increasing worldwide incidence of cancer, the constrained efficacy of standard cancer treatments, heightened understanding of cancer immunotherapy, growing investment in oncology research, and early regulatory clearances for cancer vaccines.

The cancer vaccines market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a value of $18.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. The growth observed during the forecast period can be attributed to several factors, including advancements in vaccine platforms and delivery mechanisms, the rising acceptance of personalized cancer vaccines, the broadening of clinical pipelines for therapeutic vaccines, an increase in government funding dedicated to cancer research, and the escalating demand for combination cancer therapies. Key trends expected within this period encompass the escalating development of therapeutic cancer vaccines, a heightened emphasis on personalized and targeted immunotherapies, an increase in clinical trials for innovative cancer vaccine technologies, the expansion of preventive vaccination initiatives aimed at cancer prevention, and an uptick in collaborations between pharmaceutical companies and research institutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

Which Market Drivers Are Supporting The Expansion Of The Cancer Vaccines Market?

Enhanced government financial support for research and development is projected to propel the expansion of the cancer vaccines market moving forward. Government funding refers to financial resources allocated by a government for a specific purpose. This investment in research and development is increasing to foster innovation and accelerate the creation of new technologies and treatments that can address crucial health and economic challenges. Cancer vaccines support government funding for research and development by creating opportunities for investment in preventive and therapeutic innovations, encouraging increased financial backing for vaccine research programs. For example, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, which marks a $408 million increase over 2022. Thus, the growing government funding for research and development is stimulating the growth of the cancer vaccines market.

What Segmentation Levels Are Considered In The Cancer Vaccines Market?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

What Trends Are Projected To Affect The Cancer Vaccines Market?

Leading firms within the cancer vaccines market are concentrating more on deploying quadrivalent vaccines to boost their earnings within the sector. A quadrivalent vaccine is defined as a vaccine engineered to offer protection against four distinct strains or variants of a particular virus or bacterium. An example includes Serum Institute of India, an India-based biotechnology enterprise, which introduced CERVAVAC, India’s inaugural cervical cancer vaccine, in January 2023. This vaccine targets HPV types 16 and 18, along with 6 and 11, collectively accounting for a minimum of 70% of cervical cancer cases. Administration of the vaccine will involve an injection, given in two doses for individuals aged 9–14 years, and three doses for the age group of 15 to 26.

Which Leading Firms Are Contributing To The Growth Of The Cancer Vaccines Market?

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Read the full cancer vaccines market report here:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

How Is The Cancer Vaccines Market Distributed Across Key Geographic Regions?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3452&type=smp

Browse Through More Reports Similar to the Global Cancer Vaccines Market 2026, By The Business Research Company

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Cancer Vaccines Market Across 2026–2030?

The cancer vaccines market has experienced rapid expansion in recent years. Its value is expected to rise from $9.36 billion in 2025 to $10.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. This historical growth can be linked to factors such as the increasing worldwide incidence of cancer, the constrained efficacy of standard cancer treatments, heightened understanding of cancer immunotherapy, growing investment in oncology research, and early regulatory clearances for cancer vaccines.

The cancer vaccines market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a value of $18.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. The growth observed during the forecast period can be attributed to several factors, including advancements in vaccine platforms and delivery mechanisms, the rising acceptance of personalized cancer vaccines, the broadening of clinical pipelines for therapeutic vaccines, an increase in government funding dedicated to cancer research, and the escalating demand for combination cancer therapies. Key trends expected within this period encompass the escalating development of therapeutic cancer vaccines, a heightened emphasis on personalized and targeted immunotherapies, an increase in clinical trials for innovative cancer vaccine technologies, the expansion of preventive vaccination initiatives aimed at cancer prevention, and an uptick in collaborations between pharmaceutical companies and research institutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

Which Market Drivers Are Supporting The Expansion Of The Cancer Vaccines Market?

Enhanced government financial support for research and development is projected to propel the expansion of the cancer vaccines market moving forward. Government funding refers to financial resources allocated by a government for a specific purpose. This investment in research and development is increasing to foster innovation and accelerate the creation of new technologies and treatments that can address crucial health and economic challenges. Cancer vaccines support government funding for research and development by creating opportunities for investment in preventive and therapeutic innovations, encouraging increased financial backing for vaccine research programs. For example, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, which marks a $408 million increase over 2022. Thus, the growing government funding for research and development is stimulating the growth of the cancer vaccines market.

What Segmentation Levels Are Considered In The Cancer Vaccines Market?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

What Trends Are Projected To Affect The Cancer Vaccines Market?

Leading firms within the cancer vaccines market are concentrating more on deploying quadrivalent vaccines to boost their earnings within the sector. A quadrivalent vaccine is defined as a vaccine engineered to offer protection against four distinct strains or variants of a particular virus or bacterium. An example includes Serum Institute of India, an India-based biotechnology enterprise, which introduced CERVAVAC, India’s inaugural cervical cancer vaccine, in January 2023. This vaccine targets HPV types 16 and 18, along with 6 and 11, collectively accounting for a minimum of 70% of cervical cancer cases. Administration of the vaccine will involve an injection, given in two doses for individuals aged 9–14 years, and three doses for the age group of 15 to 26.

Which Leading Firms Are Contributing To The Growth Of The Cancer Vaccines Market?

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Read the full cancer vaccines market report here:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

How Is The Cancer Vaccines Market Distributed Across Key Geographic Regions?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3452&type=smp

Browse Through More Reports Similar to the Global Cancer Vaccines Market 2026, By The Business Research Company

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer vaccines market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Cancer Vaccines Market be in 2030 compared with 2026?

The cancer vaccines market size has seen rapid growth in recent years. It is anticipated to expand from $9.36 billion in 2025 to $10.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.9%. The market’s historical growth can be linked to factors such as the increasing worldwide prevalence of cancer, the restricted efficacy of conventional cancer treatments, heightened awareness of cancer immunotherapy, escalating investment in oncology research, and prompt regulatory approvals for cancer vaccines.

The cancer vaccines market size anticipates significant expansion over the coming years, with projections indicating an increase to $18.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. This anticipated growth is primarily driven by progress in vaccine platforms and their delivery methods, the increasing embrace of personalized cancer vaccines, the widening scope of clinical pipelines for therapeutic vaccines, an increase in government investment in cancer research, and the rising need for combined cancer therapies. Key developments during this period involve the surging creation of therapeutic cancer vaccines, a heightened emphasis on personalized and targeted immunotherapies, an increase in clinical trials for innovative cancer vaccine technologies, the broadening of preventive vaccination initiatives aimed at cancer prevention, and an uptick in partnerships between pharmaceutical companies and research institutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

What Drivers Are Guiding Growth Patterns In The Cancer Vaccines Market?

Increased governmental financial backing for research and development is anticipated to drive the expansion of the cancer vaccines market moving forward. Government funding refers to monetary resources provided by a government for a specific purpose. This funding for research and development is on the rise to stimulate innovation and accelerate the creation of new technologies and treatments capable of addressing crucial health and economic challenges. Cancer vaccines assist government funding for research and development by establishing prospects for investment in both preventative and therapeutic innovations, thereby encouraging greater financial support for vaccine research programs. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, representing a $408 million increase over 2022. Therefore, the rise in government funding for research and development is propelling the growth of the cancer vaccines market.

Which Segments Are Driving Activity In The Cancer Vaccines Market?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

Which Trends Are Shaping Activity Within The Cancer Vaccines Market?

Major companies operating in the cancer vaccines market are intensifying their focus on introducing quadrivalent vaccines to maximize revenue in the market. A quadrivalent vaccine is a type of vaccine that offers protection against four different strains or types of a specific virus or bacteria. For instance, in January 2023, Serum Institute of India, an India-based biotechnology company, launched CERVAVAC, the first made-in-India cervical cancer vaccine. This vaccine is designed to be effective against HPV types 16 and 18, as well as 6 and 11, which are responsible for at least 70% of cervical cancers. The vaccine will be administered via injection in two doses among 9–14-year-olds and three doses for those between 15 and 26.

Which Key Players Are Driving Competition In The Cancer Vaccines Market?

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Which Region Is Projected To Lead The Cancer Vaccines Market During The Forecast Period?

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3452&type=smp

Browse Through More Reports Similar to the Global Cancer Vaccines Market 2026, By The Business Research Company

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Cancer Vaccines Market From 2025 To 2029?

Recently, there has been a swift expansion in the size of the cancer vaccines market. With an expected increase from $7.22 billion in 2024 to $8.25 billion in 2025, the market is projected to display a compound annual growth rate (CAGR) of 14.3%. The historic growth trajectory is tied to factors such as an upsurge in cancer incidence, heightened awareness about cancer vaccines, broadening portfolio of approved vaccines, accumulating proof of the effectiveness of such vaccines, and governmental backing for research and development.

What Is the Projected Market Size of the Cancer Vaccines Market?

Anticipations are high for significant expansion in the cancer vaccines market in the approaching years. The projections see the market soaring to $13.89 billion by 2029, advancing at a compound annual growth rate (CAGR) of 13.9%. The predicted expansion during the forecast period is credited to factors such as the use of cancer vaccines in combination therapies, heightened financial input by pharmaceutical firms, the emergence of biomarkers, tailor-made vaccines, and growing vaccine programs. The forecast period is also expected to witness several critical trends, including progress in immunology, supportive therapies, broadening of indications, patient accessibility, cooperative research, and the development of neoantigen-based and therapeutic cancer vaccines.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

Who are the Major Competitors in the Cancer Vaccines Market Outlook?

Major companies operating in the cancer vaccines market include GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

What Is Fueling Growth in the Cancer Vaccines Market?

The expected increase in global cancer cases constitutes a significant factor that could influence the expansion of the cancer vaccines market in the future. For instance, a prediction from the American Cancer Society in January 2022 states that the US could see approximately 1.9 million new cancer cases and around 609,360 deaths due to cancer, equating to an average of 1,670 deaths each day. Globally, the most prevalent types of cancer are lung, prostate, bowel, and breast cancer in females, which collectively represent 43% of all new cancer diagnoses. Consequently, the anticipated global rise in cancer occurrences is expected to stimulate the demand for the cancer vaccine market in the upcoming years.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3452&type=smp

Which Cancer Vaccines Market Segments Are Growing the Fastest?

The cancer vaccines market covered in this report is segmented –

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types

4) By End-User: Cancer Treatment Centers, Research Institutes

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

Which Industry Trends Are Shaping the Future of the Cancer Vaccines Market?

The rising global popularity of alternative treatment methods and natural remedies is likely to hamper the revenue generated by companies manufacturing cancer vaccines. Homeopathy, Ayurveda, yoga, acupuncture and sujok therapy are witnessing an increased acceptance, gradually supplanting some traditional hospital procedures. For example, Ayurvedic medicine, a traditional Indian medical system, offers a wide array of techniques and treatments specifically for cancer. As the World Health Organization (WHO) reports, plant-based treatments remain the principal source of medicine in some countries, while developing countries are leveraging the benefits of natural compounds for therapeutic uses, a situation which is impacting the sales of cancer vaccines. In addition, projections suggest that the worldwide market for homeopathic products will reach the $18.6 billion mark by 2027. This tendency is expected to persist during the forecast period, thereby restricting the demand for cancer vaccines.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Which Countries Are Leading the Cancer Vaccines Market?

The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3452

This Report Delivers Insight On:

1. How big is the cancer vaccines market, and how is it changing globally?

2. Who are the major companies in the cancer vaccines market, and how are they performing?

3. What are the key opportunities and risks in the cancer vaccines market right now?

4. Which products or customer segments are growing the most in the cancer vaccines market?

5. What factors are helping or slowing down the growth of the cancer vaccines market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cancer vaccines industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Projected CAGR for the Cancer Vaccines Market Size from 2025 to 2034?#_x000D_

There has been a rapid expansion in the size of the cancer vaccines market in the last few years. Its growth is projected to increase from $7.22 billion in 2024 to $8.25 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.3%. The surge in growth during the historical period is linked to factors such as an escalating occurrence of cancer, enhanced awareness about cancer vaccines, enlargement of the approved list of cancer vaccines, mounting evidence demonstrating the effectiveness of cancer vaccines, and government backing for research and development._x000D_

_x000D_

The market size of cancer vaccines is anticipated to experience a significant surge in the upcoming years, expanding to a value of $13.89 billion in 2029 with an expected compound annual growth rate (CAGR) of 13.9%. This market expansion in the predicted timeline is ascribed to therapies that combine with cancer vaccines, greater pharmaceutical company investment, budding biomarkers, personalized vaccines, and the broadening of vaccination programs. Noteworthy trends projected for this period encompass advancements in immunology, auxiliary therapies, indication diversification, patient access, joint research initiatives, vaccines based on neoantigens, and therapeutic vaccines for cancer._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp_x000D_

_x000D_

#What External and Internal Drivers Are Contributing to the Growth of the Cancer Vaccines Market?#_x000D_

The anticipated increase in cancer occurrences worldwide is predicted to bolster the expansion of the cancer vaccines market during the projected period. As per the American Cancer Society’s reports in January 2022, the US is expected to witness about 1.9 million new cancer diagnoses and approximately 609,360 cancer-related deaths, nearly 1,670 deaths per day. The most prevalent types of cancer globally are lung, prostate, bowel, and female breast cancer, making up 43% of all fresh cancer diagnoses. Consequently, the ascending rate of cancer incidences worldwide is forecasted to stimulate the cancer vaccine market’s need in future years._x000D_

_x000D_

#What Segment Types Define the Cancer Vaccines Market Structure?#_x000D_

The cancer vaccines market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines_x000D_

2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines_x000D_

3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types_x000D_

4) By End-User: Cancer Treatment Centers, Research Institutes_x000D_

_x000D_

Subsegments:_x000D_

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines_x000D_

2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines_x000D_

_x000D_

_x000D_

_x000D_

_x000D_

_x000D_

_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3452&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Cancer Vaccines Market?#_x000D_

The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_

_x000D_

#Which Emerging Trends that Are Influencing the Cancer Vaccines Industry Evolution?#_x000D_

The global inclination towards alternative therapies and natural cures is predicted to negatively impact the profits of companies producing cancer vaccines. Homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy treatments are progressively becoming popular alternatives to some conventional hospital procedures. For example, Ayurveda, an age-old Indian medicinal system, employs a variety of strategies and therapies for cancer. As per the World Health Organization (WHO), certain countries still rely on herbal treatments as their primary source of medicine, and emerging countries are exploring the advantages of natural substances for healing, hence affecting the sale of cancer vaccines. Furthermore, the worldwide market for homeopathic products is expected to surge to $18.6 billion by 2027. This shift is anticipated to persist over the forecast duration, curtailing the demand for cancer vaccines._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report_x000D_

_x000D_

#What Is the Definition of the Cancer Vaccines Market?#_x000D_

Cancer vaccines refer to cancer-treatment vaccinations and medications that aid the body in illness prevention and cancer treatment. They have the power to teach the immune system to recognize and eliminate dangerous microbes and cells._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3452_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model